Ayman Matta, MD
Ophthalmology · Orangeburg, NYNPI 1841288388
Payments from drug & device makers
Across 805 payments — averaging $38.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Bausch & Lomb Americas Inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Novartis$2K
- Alcon$2K
- Harrow Eye, LLC$1K
- plus $9K from 24 others
What the payments were for
- Consulting fees$6003%
- Travel & lodging$1,3736%
- Food & beverage$18,90089%
- Education$2391%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 102 | $11,895 |
| Bausch & Lomb Americas Inc. | 119 | $2,645 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $2,269 |
| Novartis | 205 | $2,211 |
| Alcon | 67 | $1,872 |
| Harrow Eye, LLC | 47 | $1,231 |
| Sun Pharmaceutical Industries Inc. | 43 | $871 |
| Mallinckrodt Hospital Products Inc. | 31 | $808 |
| Lumenis BE Inc | 1 | $796 |
| Sight Sciences, Inc. | 14 | $770 |
| Oyster Point Pharma, Inc. | 25 | $752 |
| NEW World Medical,inc. | 5 | $601 |
| Dompe US, Inc. | 17 | $578 |
| Kala Pharmaceuticals, Inc. | 20 | $447 |
| Rayner Intraocular Lenses Limited | 4 | $414 |
| Eyevance Pharmaceuticals LLC | 5 | $364 |
| Glaukos Corporation | 4 | $357 |
| Tarsus Pharmaceuticals, Inc. | 12 | $343 |
| Amgen(2 entities) | 17 | $333 |
| Biotissue Holdings Inc. | 3 | $271 |
| Heru, Inc. | 1 | $222 |
| ANI Pharmaceuticals, Inc. | 9 | $179 |
| Regeneron Healthcare Solutions, Inc. | 7 | $154 |
| Shire North American Group Inc | 13 | $147 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $115 |
| Mallinckrodt Enterprises LLC | 5 | $98 |
| Aerie Pharmaceuticals, Inc. | 4 | $84 |
| Genentech USA, Inc. | 2 | $34 |
| Optinose US, Inc. | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,666
- Tecnis 3-piece IOL$1,666
- Tecnis Symfony IOL$1,666
- Tecnis Symfony Toric IOL$1,666
- enVista MX60 IOL$1,059
- DURYSTA$829
- optilight$796
- TYRVAYA$414
- Rocklatan$391
- RayOne EMV$369
- RayOne Spheric$369
- RayOne Aspheric$369
- OMNI(R) SURGICAL SYSTEM (US)$345
- Tobradex ST$295
- Oxervate$290
- INVELTYS$290
- EYSUVIS$290
- enVista Aspire IOL$279
- iStent inject Trabecular Micro-Bypass Stent System$276
- AmnioGraft$255
How this compares
$30,889 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 816 | $909,571 |
| MieboPerfluorohexyloctane/Pf | 786 | $816,680 |
| XiidraLifitegrast | 625 | $704,061 |
| Cyclosporine | 352 | $208,575 |
| VevyeCyclosporine | 103 | $84,183 |
| CequaCyclosporine | 93 | $81,751 |
| LumiganBimatoprost | 140 | $74,514 |
| VascepaIcosapent Ethyl | 92 | $48,638 |
| ZyletTobramycin/Lotepred Etab | 97 | $48,295 |
| Bepotastine Besilate | 230 | $46,302 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $34,851 |
| EysuvisLoteprednol Etabonate | 60 | $33,216 |
| Restasis MultidoseCyclosporine | 36 | $33,146 |
| VyzultaLatanoprostene Bunod | 61 | $29,696 |
| CombiganBrimonidine Tartrate/Timolol | 66 | $26,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $2,645 | $1,550,4371,472 claims |
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan, Alphagan P | $11,895 | $1,053,4201,086 claims |
| Harrow Eye, LLCVevye | $1,231 | $84,183103 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $871 | $81,75193 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Prolensa, Loteprednol Etabonate | $115 | $73,737186 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $84 | $34,85161 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $447 | $33,21660 claims |
| AlconSimbrinza | $1,872 | $17,49772 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $364 | $7,09527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Orangeburg
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.